Free Trial
NASDAQ:QNCX

Quince Therapeutics Q1 2024 Earnings Report

Quince Therapeutics logo
$1.03 -0.01 (-0.96%)
As of 12:55 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Quince Therapeutics EPS Results

Actual EPS
-$0.26
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Quince Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quince Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Sunday, May 12, 2024
Conference Call Time
6:00PM ET

Upcoming Earnings

Quince Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025

Quince Therapeutics Earnings Headlines

Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Quince Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quince Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quince Therapeutics and other key companies, straight to your email.

About Quince Therapeutics

Quince Therapeutics (NASDAQ:QNCX), a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

View Quince Therapeutics Profile

More Earnings Resources from MarketBeat